Antifungal prophylaxis in lung transplantation

Research output: Contribution to journalArticlepeer-review

Abstract

Fungal infections are among the most serious complications of lung transplantation. The 1-year cumulative incidence of invasive fungal infections in lung transplant recipients is 6 to 10%, which is higher than most other solid organ transplant recipients. Aspergillus spp. are the most common etiologic agents, but Candida spp., non-Aspergillus mycelial fungi, Cryptococcus, Pneumocystis, and endemic mycoses can cause active infections in this population. Clinical manifestations of fungal infection in lung transplant recipients are protean, and include invasive pulmonary disease, airway and anastomotic infections, posttransplant empyemas, and disseminated infections. Most centers employ either universal or targeted antifungal prophylaxis in some form, but the agents, doses, durations, and monitoring strategies vary widely from one center to another. This review discusses the salient fungal organisms responsible for infection in lung transplant recipients and management strategies for prevention.

Original languageEnglish (US)
Pages (from-to)717-726
Number of pages10
JournalSeminars in Respiratory and Critical Care Medicine
Volume32
Issue number6
DOIs
StatePublished - 2011
Externally publishedYes

Keywords

  • Fungal prophylaxis
  • aspergillosis
  • invasive fungal infections
  • lung transplant
  • mold infection

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Fingerprint

Dive into the research topics of 'Antifungal prophylaxis in lung transplantation'. Together they form a unique fingerprint.

Cite this